NASDAQ:ILMN - Illumina Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $308.23 -2.95 (-0.95 %) (As of 11/15/2018 01:02 AM ET)Previous Close$311.18Today's Range$306.30 - $314.5252-Week Range$203.83 - $372.61Volume718,299 shsAverage Volume932,788 shsMarket Capitalization$45.63 billionP/E Ratio77.06Dividend YieldN/ABeta1.07 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California. Receive ILMN News and Ratings via Email Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:ILMN Previous Symbol CUSIP45232710 Webwww.illumina.com Phone858-202-4500 Debt Debt-to-Equity Ratio0.24 Current Ratio2.46 Quick Ratio2.24 Price-To-Earnings Trailing P/E Ratio77.06 Forward P/E Ratio53.61 P/E Growth2.3 Sales & Book Value Annual Sales$2.75 billion Price / Sales16.46 Cash Flow$5.2852 per share Price / Cash58.32 Book Value$24.45 per share Price / Book12.61 Profitability EPS (Most Recent Fiscal Year)$4.00 Net Income$726 million Net Margins21.09% Return on Equity27.10% Return on Assets14.78% Miscellaneous Employees6,200 Outstanding Shares147,000,000Market Cap$45.63 billion OptionableOptionable Illumina (NASDAQ:ILMN) Frequently Asked Questions What is Illumina's stock symbol? Illumina trades on the NASDAQ under the ticker symbol "ILMN." How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Tuesday, October, 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.26. The life sciences company earned $853 million during the quarter, compared to analysts' expectations of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business's revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.11 earnings per share. View Illumina's Earnings History. When is Illumina's next earnings date? Illumina is scheduled to release their next quarterly earnings announcement on Tuesday, January 29th 2019. View Earnings Estimates for Illumina. What guidance has Illumina issued on next quarter's earnings? Illumina updated its FY18 earnings guidance on Tuesday, October, 23rd. The company provided EPS guidance of $5.70-$5.75 for the period, compared to the Thomson Reuters consensus estimate of $5.45. Illumina also updated its FY 2018 guidance to $5.70-5.75 EPS. What price target have analysts set for ILMN? 18 brokerages have issued 1 year target prices for Illumina's shares. Their predictions range from $250.00 to $400.00. On average, they expect Illumina's share price to reach $329.4375 in the next year. This suggests a possible upside of 6.9% from the stock's current price. View Analyst Price Targets for Illumina. What is the consensus analysts' recommendation for Illumina? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina. Has Illumina been receiving favorable news coverage? News articles about ILMN stock have trended neutral recently, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Illumina earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned media stories about the life sciences company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the next few days. Who are some of Illumina's key competitors? Some companies that are related to Illumina include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO). Who are Illumina's key executives? Illumina's management team includes the folowing people: Mr. Jay T. Flatley, Exec. Chairman (Age 65)Mr. Francis A. deSouza, CEO, Pres & Director (Age 47)Mr. Sam A. Samad, CFO & Sr. VP (Age 48)Mr. Omead Ostadan, Exec. VP of Operations and Products (Age 46)Mr. Marc A. Stapley, Exec. VP of Strategy & Corp. Devel. (Age 48) Who are Illumina's major shareholders? Illumina's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (10.98%), Capital Research Global Investors (5.35%), Jennison Associates LLC (3.28%), Edgewood Management LLC (2.99%), Capital International Investors (2.75%) and Jackson Square Partners LLC (0.97%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Daniel Bradbury, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Institutional Ownership Trends for Illumina. Which major investors are selling Illumina stock? ILMN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Capital World Investors, AMP Capital Investors Ltd, Edgewood Management LLC, Baillie Gifford & Co., Assenagon Asset Management S.A., Mitsubishi UFJ Trust & Banking Corp and Eagle Asset Management Inc.. Company insiders that have sold Illumina company stock in the last year include A Blaine Bowman, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Insider Buying and Selling for Illumina. Which major investors are buying Illumina stock? ILMN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Canada Pension Plan Investment Board, Jennison Associates LLC, WCM Investment Management CA, Nan Shan Life Insurance Co. Ltd., First Trust Advisors LP, Korea Investment CORP and Jackson Square Partners LLC. View Insider Buying and Selling for Illumina. How do I buy shares of Illumina? Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Illumina's stock price today? One share of ILMN stock can currently be purchased for approximately $308.23. How big of a company is Illumina? Illumina has a market capitalization of $45.63 billion and generates $2.75 billion in revenue each year. The life sciences company earns $726 million in net income (profit) each year or $4.00 on an earnings per share basis. Illumina employs 6,200 workers across the globe. What is Illumina's official website? The official website for Illumina is http://www.illumina.com. How can I contact Illumina? Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected] MarketBeat Community Rating for Illumina (NASDAQ ILMN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 885 (Vote Outperform)Underperform Votes: 786 (Vote Underperform)Total Votes: 1,671MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?